An update on breast cancer prevention trials
- PMID: 17010056
- DOI: 10.1111/j.1525-1438.2006.00679.x
An update on breast cancer prevention trials
Abstract
In recent years, the question of whether breast cancer can be prevented has been examined in a number of large clinical trials, employing either selective estrogen receptor modifiers such as tamoxifen and raloxifene or aromatase inhibitors. In this paper, we review the most prominent studies, all of which are either under way or in follow-up.
Similar articles
-
Prevention of breast cancer using SERMs and aromatase inhibitors.J Mammary Gland Biol Neoplasia. 2003 Jan;8(1):5-18. doi: 10.1023/a:1025727103811. J Mammary Gland Biol Neoplasia. 2003. PMID: 14587860 Review.
-
Chemoprevention of breast cancer.Curr Probl Cancer. 2004 Jul-Aug;28(4):201-17. doi: 10.1016/j.currproblcancer.2004.05.007. Curr Probl Cancer. 2004. PMID: 15318323 Review. No abstract available.
-
Role of antiestrogens and aromatase inhibitors in breast cancer treatment.Curr Opin Obstet Gynecol. 2002 Feb;14(1):5-12. doi: 10.1097/00001703-200202000-00002. Curr Opin Obstet Gynecol. 2002. PMID: 11801870 Review.
-
Upstaging tamoxifen? New classes of drugs emerging for breast cancer.J Natl Cancer Inst. 2002 Apr 3;94(7):474-5. doi: 10.1093/jnci/94.7.474. J Natl Cancer Inst. 2002. PMID: 11929942 No abstract available.
-
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.JAMA. 2019 Sep 3;322(9):868-886. doi: 10.1001/jama.2019.5780. JAMA. 2019. PMID: 31479143
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical